Stock Titan Trading tools for traders and investors.

-

09:00:14 PM

Last BCRX Stock Market News

BCRX - Biocryst Pharmaceuticals Inc.

03/02/21 7:00 AM

Nasdaq : BCRX

BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO(TM) (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has submitted a marketing authorization application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) seeking

RHEA-AI

very positive

02/25/21 4:15 PM

Nasdaq : BCRX

BioCryst Receives Positive CHMP Opinion for ORLADEYO(TM) (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion

RHEA-AI

very positive

02/25/21 7:00 AM

Nasdaq : BCRX

BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones

--ORLADEYO(TM) (berotralstat) now approved in U.S. and Japan; EU approval expected in Q2-- --Dose-ranging trial of BCX9930 has fully enrolled 16 PNH patients; Data to be presented at R&D day March 22 -- --Company adds $325 million in financing in Q4 2020; Year-end cash of $303 million provides cash runway

RHEA-AI

neutral

02/18/21 7:00 AM

Nasdaq : BCRX

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Cowen 41 st Annual Healthcare Conference on Thursday, March 4, 2021 at 12:10 p.m. ET and the Barclays Annual Healthcare Conference on

RHEA-AI

neutral

02/11/21 7:00 AM

Nasdaq : BCRX

BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. BioCryst management will host a conference call and

RHEA-AI

neutral

02/09/21 7:15 AM

Nasdaq : BCRX

BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that data on ORLADEYO(TM) (berotralstat) will be presented at the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held virtually

RHEA-AI

neutral

02/03/21 7:00 AM

Nasdaq : BCRX

BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB(R) Expanding Patient Population to Include Children Six Months and Older

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application for RAPIVAB (R) (peramivir injection) expanding the patient population of

RHEA-AI

neutral

01/22/21 7:00 AM

Nasdaq : BCRX

BioCryst Announces Approval of ORLADEYO(TM) (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO (TM) (berotralstat) 150 mg for

RHEA-AI

very positive

01/07/21 7:00 AM

Nasdaq : BCRX

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees inducement options to purchase an aggregate of 240,500 shares of BioCryst

RHEA-AI

very positive

01/06/21 7:00 AM

Nasdaq : BCRX

BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39 th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40

RHEA-AI

neutral